雌孕激素受体与P53、bcl-2基因蛋白在大肠良恶性病变中表达的相关性研究

目的探讨ER、PR、P53、bcl-2在大肠良恶性病变中的表达相关性.方法利用ER、PR、P53及bcl-2特异性抗体对75例大肠良恶性肿瘤进行SABC免疫组织化学染色.结果四种抗体联合表达率在47例大肠恶性肿瘤、28例良性增生性疾病和41例癌旁移行区粘膜分别为26.83%、10.7%和0.10例大肠息肉P53和bcl-2均无表达,41例癌旁移行区未见P53表达.ER、PR联合表达率在大肠癌(42.55%)明显高于癌旁(17.07%),P53和bcl-2联合表达率在癌、良性增生和癌旁分别为48.94%、17.80%和0,三者间差异显著.而四种抗体表达与患者性别、年龄无关.结论ER、PR、P53和bcl-2表达与大肠肿瘤发生有关.P53基因突变是人类大肠癌发生的最常见的遗传学改变之一,bcl-2是大肠癌发生的早期分子水平标志;激素及其受体改变促进肿瘤的发生并且雌、孕激素受体水平与肿瘤的病理分化程度有关.

Study on Relationship of ER,PR,P53 or Bcl -2 Expressions in Colorectal Benign and Malignant Tumors

Objective: To explore the correlationship of ER.PR.P53 and bcl - 2 expressions in colorectal benign and malignant tumors. Methods:SABC immmunohistochemical staining was employed in this study. 75 colorectal benign and malignant tumors were examined using antibodies specific to ER.PR.P53 and bcl - 2 . Results: co - overexpression rates of these 4 items studied were 26.83% in the malignant tumors(7/47), 10.7% in benign proliferative lesions (3/28), zero in mucosa tissues adjacent to the primary cancer (MA) (0/41). 10 large intestine polyps were all negative for P53 or bcl - 2 expression. 41 MA were negative for P53. Co - expression rate of ER and PR in large intestine carcinoma (42.55%) was significantly higher than that in MA( 17. 07%). Co-expression rates of P53 and bcl - 2 were 48. 9%, 17.86% and 0, respectively, in large intestine carcinoma, benign proliferative lesions and MA. Significant differences existed between each other. However, expressions of ER.PR.P53 or bcl - 2 were unrelated with the sex and ageof the patients. Conclusion:The expressions of ER .PR.P53 and bcl-2 correlates with occurrence of the large intestine carcinoma. Mutation of P53 gene is one of the commonest genetic changes in the development of human colorectal cancer, and bcl - 2 is an early molecular marker of carcinomagenesis. The changes of hormones and corresponding receptors may predispose to occurrence of tumors and ER, PR were associated with the pathological differentiation of tumor.